Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Intramuscular marginally better than buccal midazolam for paediatric seizure

01 Aug 2020

Intramuscular midazolam appears to be better than buccal administrations for first-line treatment of paediatric seizures, a recent study has found.

Researchers enrolled 150 children with active seizures. Half of the participants received midazolam intramuscularly (mean age, 49±46 months), while the other half were given buccal midazolam (mean age, 45±37 months). The primary efficacy outcome was the proportion of patients with seizure cessation within 5 minutes of drug administration.

Thirty-two children saw cessation of seizure within 5 minutes of buccal midazolam administration, yielding a rate of 46 percent. In comparison 41 patients in the intramuscular arm achieved the efficacy endpoint, with a rate of 61 percent. The absolute difference was of borderline significance (15.5 percent; p=0.07).

Moreover, the average time from medication administration to seizure cessation was marginally shorter in the intramuscular midazolam group (15.9±28.7 vs 17.8±27.5 minutes; p=0.69). Cox regression analysis showed that the duration of seizures after intramuscular vs buccal midazolam was 13 percent shorter, though significance was not achieved (p=0.49).

In terms of safety, one patient in the intramuscular arm developed respiratory depression and hypotension within 3 minutes of medication administration. Patient recovered fully with intervention and within 15 minutes after drug administration. Such an event was not observed in the buccal midazolam group.

“We conclude that the efficacy and safety of intramuscular midazolam as first-line treatment for paediatric seizures compares favourably to buccal midazolam,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.